Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis. Issue 1 (4th December 2021)

• Record Type: Journal Article
• Authors: Wijetunga, N Ari; Boire, Adrienne; Young, Robert J; Yamada, Yoshiya; Wolden, Suzanne; Yu, Helena; Kris, Mark; Seidman, Andrew; Betof-Warner, Allison; Diaz, Maria; Reiner, Anne; Malani, Rachna; Pentsova, Elena; Yang, Jonathan T
• Is Part Of: Neuro-oncology advances. Volume 3:Issue 1(2021)
• Publication Date: 2021-12-04
• Subjects: central nervous system -- circulating tumor cells -- craniospinal irradiation -- leptomeningeal metastases -- proton therapy; 616.99481
• DOI: 10.1093/noajnl/vdab181
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: Background: Leptomeningeal metastasis (LM) involves cerebrospinal fluid (CSF) seeding of tumor cells. Proton craniospinal irradiation (pCSI) is potentially effective for solid tumor LM. We evaluated whether circulating tumor cells (CTCs) in the CSF (CTCCSF ), blood (CTCblood ), and neuroimaging correlate with outcomes after pCSI for LM. Methods: We describe a single-institution consecutive case series of 58 patients treated with pCSI for LM. Pre-pCSI CTCs, the change in CTC post-pCSI (Δ CTC ), and MRIs were examined. Central nervous system progression-free survival (CNS-PFS) and overall survival (OS) from pCSI were determined using Kaplan Meier analysis, Cox proportional-hazards regression, time-dependent ROC analysis, and joint modeling of time-varying effects and survival outcomes. Results: The median CNS-PFS and OS were 6 months (IQR: 4–9) and 8 months (IQR: 5–13), respectively. Pre-pCSI CTCCSF < 53/3mL was associated with improved CNS-PFS (12.0 vs 6.0 months, P < .01). Parenchymal brain metastases ( n = 34, 59%) on pre-pCSI MRI showed worse OS (7.0 vs 13 months, P = .01). Through joint modeling, CTCCSF was significantly prognostic of CNS-PFS ( P < .01) and OS ( P < .01). A Δ CTC-CSF ≥37 cells/3mL, the median Δ CTC-CSF at nadir, showed improved CNS-PFS (8.0 vs 5.0 months, P = .02) and further stratified patients into favorable and unfavorable subgroups (CNS-PFS 8.0 vs 4.0 months, P < .01). No associations with CTCblood were found. Conclusion: We found the best survival observed in patients with low pre-pCSI CTCCSF and intermediate outcomes for patients with high pre-pCSI CTCCSF but large Δ CTC-CSF . These results favor additional studies incorporating pCSI and CTCCSF measurement earlier in the LM treatment paradigm.